Trial Profile
A Multi-centre Phase II Study to Determine the Response Kinetics, Safety and Efficacy of Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma Considered Unsuitable for ABVD
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms PLIMATH
- 15 Jun 2023 Results presented at the 28th Congress of the European Haematology Association
- 03 Nov 2022 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 03 Nov 2022 Planned primary completion date changed from 1 May 2022 to 1 Apr 2023.